Harmonix Fund

Harmonix Fund is a California-based venture capital firm specializing in early-stage investments within the healthcare, life sciences, and deep tech sectors. The firm partners with exceptional entrepreneurs to advance human health and improve quality of life through meaningful innovations. Their multidisciplinary team comprises entrepreneurs, scientists, operators, and industry experts, collectively bringing decades of experience to drive transformative change.

The firm's investment strategy focuses on sectors such as biotechnology, healthcare, artificial intelligence, machine learning, medical devices, pharmaceuticals, software, and space tech. Harmonix Fund primarily invests in early-stage companies, including Series A and Series B rounds, with investment sizes ranging from $5 million to $20 million. Their geographical focus is on the United States, aiming to support startups that are poised to benefit humanity and create a more harmonious society.

Harmonix Fund has a proven track record of identifying and nurturing breakthrough technologies. Their diverse portfolio includes companies like Bit.Bio, a platform programming the software of life; Volumetric, a 3D bioprinting platform for drug research and human organ replacements; and Insilico Medicine, an AI drug discovery and development platform. The firm has successfully closed multiple funds, with Harmonix Fund III closing on October 31, 2024, and Fund I closing in July 2023. Their investments have led to significant advancements in healthcare and deep tech, demonstrating their commitment to supporting innovations that have the potential to revolutionize industries and improve lives.